Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AP2.0 Bifidobacterium longum subsp. infantis
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
AP2.0 Bifidobacterium longum subsp. infantis is an oral, colon-targeted live biotherapeutic formulation consisting of the probiotic strain *Bifidobacterium longum subsp. infantis* GIM 1.207 encapsulated within an enzyme-triggered, fuse-like microcapsule known as AP2.0. This delivery system is designed to protect the probiotics from the acidic environment of the stomach and bile salts in the small intestine, ensuring targeted release in the colon where microbial enzymes trigger the degradation of the capsule. Once released, the probiotics colonize the intestinal mucosa and modulate the gut microbiota by increasing the abundance of beneficial taxa such as *Bacteroidetes* and *Firmicutes* (including *Odoribacter* and *Ruminococcaceae*). This restoration of microbial homeostasis leads to a reduction in pro-inflammatory cytokines and systemic inflammation, making it a potential therapeutic candidate for the treatment of ulcerative colitis.
- Other names
- AP2.0-encapsulated Bifidobacterium longum subsp. infantisAP-2.0-encapsulated Bifidobacterium longum subsp. infantisAP 2.0-encapsulated Bifidobacterium longum subsp. infantisBifidobacterium longum subsp. infantis GIM 1.207AP2.0-encapsulated Bl.infantisAP-2.0-encapsulated Bl.infantisAP 2.0-encapsulated Bl.infantis
Beyond the preview
Go deeper on AP2.0 Bifidobacterium longum subsp. infantis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AP2.0 Bifidobacterium longum subsp. infantis.